Neumora Therapeutics, Inc. announced the initiation of a Phase 1 single ascending dose /multiple ascending dose study evaluating NMRA-266 in healthy adult participants. NMRA-266 is a highly selective positive allosteric modulator of the M4 muscarinic receptor that Neumora is developing as a treatment for schizophrenia and other neuropsychiatric disorders. Neumora believes that as a selective M4 receptor-positive allosteric modulator, NMRA-266 has the potential to deliver antipsychotic efficacy, while minimizing the side effects associated with current antipsychotics and other non-selective muscarinic agonists.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
9.17 USD | -1.50% | -5.17% | -46.22% |
14/05 | Neumora Therapeutics Begins Phase 2 Study of Navacaprant in Bipolar Depression | MT |
14/05 | Neumora Therapeutics, Inc. Announces Initiation of Phase 2 Study of Navacaprant in Bipolar Depression | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-46.22% | 146.28Cr | |
+67.53% | 6.39TCr | |
-0.77% | 4.18TCr | |
+44.98% | 4.07TCr | |
-10.87% | 2.71TCr | |
+13.30% | 2.65TCr | |
-22.79% | 1.87TCr | |
+4.70% | 1.27TCr | |
+24.10% | 1.21TCr | |
+27.41% | 1.21TCr |
- Stock Market
- Equities
- NMRA Stock
- News Neumora Therapeutics, Inc.
- Neumora Therapeutics, Inc. Announces NMRA-266 IND Clearance and Initiation of Phase 1 Clinical Study